Johnnie José Orozco, MD, PhD
Associate Professor
Translational Science and Therapeutics Division, Fred Hutch
Dr. Johnnie José Orozco is a practicing oncologist who studies novel ways to make the transplantation of blood-forming stem cells safer and more effective. His research tests radioimmunotherapies that use immune system proteins known as antibodies to selectively target radioactivity to cancer cells, sparing normal tissues. The antibody and its radioactive payload locate and kill tumor cells by damaging their DNA.
Dr. Orozco’s research is primarily focused on partially matched transplantation, in which the recipient and the donor do not share all of the genetic markers that are used for tissue matching. This is of particular importance to racial and ethnic minorities who need transplants but cannot find a fully matched donor from transplant registries, in which donors are predominately non-Hispanic whites. His goal is to extend the benefits of transplantation to more people by making it safer for patients whose only option may be a partial match.
Other Appointments & Affiliations
Associate Professor, Division of Hematology and Oncology, University of Washington School of MedicineAssociate Professor, Division of Hematology and Oncology
University of Washington School of Medicine
Attending Physician
Fred Hutchinson Cancer Center
Education
Research Associate, Clinical Research Division, Fred Hutch; 2013-2015
Fellowship, Hematology / Oncology Program, University of Washington; 2009-2012
Internal Medicine Residency, University of California, San Francisco; 2006-2009
MD, Medical Scientist Training Program, University of Washington School of Medicine; 2006
PhD, Bioengineering, University of Washington; 2004
BS, Chemical Engineering, University of California, Los Angeles; 1995
Current Projects
In ongoing studies, Dr. Orozco is working to identify the ideal alpha radionuclide to be used in radioimmunotherapies that can reduce relapse risks after transplantation, including transplants in which haploidentical (half-matched) family members serve as donors. Using a murine leukemia model, he is testing 90Y, 211At and 131I bound antibodies that recognize a molecule called CD45 that is found on most blood cells, including leukemia cells. He is working to identify optimal chemotherapy combinations and radiation doses as well as the ideal radionuclide that produce the best stem cell engraftment and survival with the lowest toxicities.